Demographic and risk group heterogeneity across the UNAIDS 90-90-90 targets: a systematic review and meta-analysis protocol.

90-90-90 Africa Antiretroviral therapy Care cascade HIV HIV diagnosis Meta-analysis Risk-factors Systematic review Viral suppression Virological suppression

Journal

Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575

Informations de publication

Date de publication:
06 05 2019
Historique:
received: 15 05 2018
accepted: 12 04 2019
entrez: 8 5 2019
pubmed: 8 5 2019
medline: 6 5 2020
Statut: epublish

Résumé

Despite policies for universal HIV testing and treatment (UTT) regardless of CD4 count, there are still 1.8 million new HIV infections and 1 million AIDS-related deaths annually. The UNAIDS 90-90-90 goals target suppression of HIV viral load in 73% of all HIV-infected people worldwide by 2030. However, achieving these targets may not lead to expected reductions in HIV incidence if the remaining 27% (persons with unsuppressed viral load) are the drivers of HIV transmission through high-risk behaviors. We aim to conduct a systematic review and meta-analysis to understand the demographics, mobility, geographic distribution, and risk profile of adults who are not virologically suppressed in sub-Saharan Africa in the era of UTT. We will review the published and grey literature for study sources that contain data on demographic and behavioral strata of virologically suppressed and unsuppressed populations since 2014. We will search PubMed and Embase using four sets of search terms tailored to identify characteristics associated with virological suppression (or lack thereof) and each of the individual 90-90-90 goals. Record screening and data abstraction will be done independently and in duplicate. We will use random effects meta-regression analyses to estimate the distribution of demographic and risk features among groups not virologically suppressed and for each individual 90-90-90 goal. The results of our review will help elucidate factors associated with failure to achieve virological suppression in sub-Saharan Africa, as well as factors associated with failure to achieve each of the 90-90-90 goals. These data will help quantify the population-level effects of current HIV treatment interventions to improve strategies for maximizing virological suppression and ending the HIV epidemic. PROSPERO CRD42018089505 .

Sections du résumé

BACKGROUND
Despite policies for universal HIV testing and treatment (UTT) regardless of CD4 count, there are still 1.8 million new HIV infections and 1 million AIDS-related deaths annually. The UNAIDS 90-90-90 goals target suppression of HIV viral load in 73% of all HIV-infected people worldwide by 2030. However, achieving these targets may not lead to expected reductions in HIV incidence if the remaining 27% (persons with unsuppressed viral load) are the drivers of HIV transmission through high-risk behaviors. We aim to conduct a systematic review and meta-analysis to understand the demographics, mobility, geographic distribution, and risk profile of adults who are not virologically suppressed in sub-Saharan Africa in the era of UTT.
METHODS
We will review the published and grey literature for study sources that contain data on demographic and behavioral strata of virologically suppressed and unsuppressed populations since 2014. We will search PubMed and Embase using four sets of search terms tailored to identify characteristics associated with virological suppression (or lack thereof) and each of the individual 90-90-90 goals. Record screening and data abstraction will be done independently and in duplicate. We will use random effects meta-regression analyses to estimate the distribution of demographic and risk features among groups not virologically suppressed and for each individual 90-90-90 goal.
DISCUSSION
The results of our review will help elucidate factors associated with failure to achieve virological suppression in sub-Saharan Africa, as well as factors associated with failure to achieve each of the 90-90-90 goals. These data will help quantify the population-level effects of current HIV treatment interventions to improve strategies for maximizing virological suppression and ending the HIV epidemic.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42018089505 .

Identifiants

pubmed: 31060607
doi: 10.1186/s13643-019-1024-6
pii: 10.1186/s13643-019-1024-6
pmc: PMC6501385
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110

Références

BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Lancet. 2011 Jan 8;377(9760):108-9
pubmed: 20630580
AIDS. 2017 Nov 13;31(17):2427-2429
pubmed: 28926401
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Sci Rep. 2017 Nov 23;7(1):16117
pubmed: 29170407
PLoS One. 2014 Jan 15;9(1):e84511
pubmed: 24454728
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919

Auteurs

Dylan Green (D)

Departments of Epidemiology and Global Health, University of Washington, 1959 NE Pacific St, Seattle, 98195, Washington, USA. greend7@uw.edu.
Strategic Analysis, Research & Training (START) Center, University of Washington, 1510 San Juan Rd NE, 3rd floor, Seattle, Washington, 98195, USA. greend7@uw.edu.

Brenda Kharono (B)

Departments of Epidemiology and Global Health, University of Washington, 1959 NE Pacific St, Seattle, 98195, Washington, USA.
Strategic Analysis, Research & Training (START) Center, University of Washington, 1510 San Juan Rd NE, 3rd floor, Seattle, Washington, 98195, USA.

Diana M Tordoff (DM)

Departments of Epidemiology and Global Health, University of Washington, 1959 NE Pacific St, Seattle, 98195, Washington, USA.
Strategic Analysis, Research & Training (START) Center, University of Washington, 1510 San Juan Rd NE, 3rd floor, Seattle, Washington, 98195, USA.

Adam Akullian (A)

Departments of Epidemiology and Global Health, University of Washington, 1959 NE Pacific St, Seattle, 98195, Washington, USA.
Institute for Disease Modeling, 3150 139th Ave SE, Building IV, Bellevue, 98005, Washington, USA.

Anna Bershteyn (A)

Institute for Disease Modeling, 3150 139th Ave SE, Building IV, Bellevue, 98005, Washington, USA.

Michelle Morrison (M)

Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, 98109, Washington, USA.

Geoff Garnett (G)

Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, 98109, Washington, USA.

Ann Duerr (A)

Departments of Epidemiology and Global Health, University of Washington, 1959 NE Pacific St, Seattle, 98195, Washington, USA.
Strategic Analysis, Research & Training (START) Center, University of Washington, 1510 San Juan Rd NE, 3rd floor, Seattle, Washington, 98195, USA.
HIV Vaccine Trials Network, Vaccine and Infectious Disease and Public Health Science Divisions, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, 98109, Washington, USA.

Paul Drain (P)

Departments of Epidemiology and Global Health, University of Washington, 1959 NE Pacific St, Seattle, 98195, Washington, USA.
Strategic Analysis, Research & Training (START) Center, University of Washington, 1510 San Juan Rd NE, 3rd floor, Seattle, Washington, 98195, USA.
Division of Allergy and Infectious Diseases, Department of Medicine, School of Medicine, University of Washington, 1959 NE Pacific St, Seattle, 98195, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH